Cyclin-dependent kinase 3 (Cdk3) is a member of the cyclin-dependent kinase family, which plays crucial roles in regulating the cell cycle progression and cell division. Unlike other Cdks, Cdk3 lacks a known cyclin partner, making its activation and function less understood compared to other Cdks. However, accumulating evidence suggests that Cdk3 may participate in various cellular processes beyond cell cycle regulation, including transcriptional regulation, neuronal differentiation, and cellular senescence. Despite its elusive nature, Cdk3 has been implicated in the control of G1/S transition in the cell cycle, where it may phosphorylate key substrates involved in DNA replication and cell proliferation. Moreover, dysregulation of Cdk3 activity has been associated with several human diseases, including cancer and neurodegenerative disorders, highlighting its significance in cellular homeostasis and disease pathogenesis.
The activation of Cdk3 involves intricate mechanisms that regulate its kinase activity and substrate specificity. Although Cdk3 lacks a classical cyclin partner, its activity may be modulated by alternative mechanisms, such as post-translational modifications and protein-protein interactions. Phosphorylation of specific residues within the Cdk3 protein may enhance its kinase activity or stabilize its interaction with substrates, thereby promoting cell cycle progression or other cellular processes. Additionally, Cdk3 activity may be regulated by the availability of activating cofactors or the presence of inhibitory proteins that modulate its enzymatic activity. Furthermore, environmental cues and intracellular signaling pathways may influence Cdk3 activation through the induction or suppression of upstream regulators or modulators of Cdk3 function. Overall, elucidating the mechanisms of Cdk3 activation provides valuable insights into its physiological roles and strategies for targeting Cdk3-associated diseases.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW8510 | 222036-17-1 | sc-215122 sc-215122A | 1 mg 5 mg | $293.00 $626.00 | 8 | |
GW8510 is a Cdk2/CDK3 inhibitor that affects the activity of Cdk3 by indirectly regulating its expression and function through the inhibition of Cdk2, a closely related cyclin-dependent kinase. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438 is a CDK1/2/9 inhibitor that indirectly influences Cdk3 by modulating the overall cell cycle dynamics, allowing the activation of Cdk3 through its interaction with cell cycle regulators. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $291.00 $341.00 $1046.00 $3126.00 | 1 | |
AT7519 is a CDK inhibitor that indirectly influences Cdk3 by modulating the overall cell cycle dynamics, allowing the activation of Cdk3 through its interaction with cell cycle regulators. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A is a CDK1/CDK2/CDK3 inhibitor that indirectly influences Cdk3 by modulating the overall cell cycle dynamics, allowing the activation of Cdk3 through its interaction with cell cycle regulators. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol is a CDK inhibitor that indirectly activates Cdk3 by affecting the cell cycle progression and enabling Cdk3 activation through its regulatory partners. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a CDK2/CDK7/CDK9 inhibitor that indirectly influences Cdk3 by modulating the overall cell cycle dynamics, allowing the activation of Cdk3 through its interaction with cell cycle regulators. | ||||||
NU6027 | 220036-08-8 | sc-215591 | 10 mg | $156.00 | 1 | |
NU6027 is a CDK inhibitor that indirectly activates Cdk3 by affecting the cell cycle progression and enabling Cdk3 activation through its regulatory partners. | ||||||